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Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 32 prioritisation (August 2017), 10 drugs were filtered out of 366 identified and were sent to 
prioritisation. Of these, 5 drugs were ranked as ‘highly relevant’ by the expert panel, 5 as ‘relevant’ 
and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 32
nd
 prioritisation 3
rd
 quarter 2017 
Overall 
category 
1. 
Ceritinib (Zykadia®) versus chemotherapy in patients with ALK-rearranged non-small-
cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5) Relevant 
2. 
Brigatinib (AlunbrigTM) in patients with crizotinib-refractory anaplastic lymphoma kinase–
positive non–small-cell lung cance Relevant 
3. 
Cisplatin plus etoposide with or without bevacizumab (Avastin®) as first-line treatment in 
extensive-disease small-cell lung cancer Relevant 
4. 
Bevacizumab (Avastin®) and paclitaxel–carboplatin chemotherapy and secondary 
cytoreduction in recurrent, platinum-sensitive ovarian cancer 
Highly 
relevant 
5. Adjuvant pertuzumab (Perjeta®) and trastuzumab in early HER2-positive breast cancer Relevant 
6. 
Olaparib (Lynparza®) for metastatic breast cancer in patients with a germline BRCA 
mutation 
Highly 
relevant 
7. 
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone 
receptor-positive, HER2-negative, advanced breast cancer (BELLE-2) Relevant 
8. 
Idelalisib (Zydelig®) or placebo in combination with bendamustine and rituximab in 
patients with relapsed or refractory chronic lymphocytic leukaemia 
Highly 
relevant 
9. 
Midostaurin (Rydapt®) plus chemotherapy for acute myeloid leukemia with a FLT3 
mutation 
Highly 
relevant 
10. 
Abiraterone (Zytiga®) in combination with prednisone androgen-deprivation therapy in 
metastatic, castration-sensitive prostate cancer 
Highly 
relevant 
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1 Breast cancer 
1.1 Olaparib (Lynparza®) for metastatic breast cancer in patients 
with a germline BRCA mutation 
 
Overview 
Drug Description a poly (ADP-ribose) polymerase (PARP) inhibitor 
Patient Indication 
Olaparib for the treatment of patients with germline BRCA mutation and 
human epidermal growth factor receptor type 2 (HER2)–negative 
metastatic breast cancer who had received no more than two previous 
chemotherapy regimens for metastatic disease 
Incidence in 
Austria 
5,454 newly diagnosed per year (2014), 64.3 /100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02000622 until 12/2018 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
12/2014: as monotherapy for the maintenance treatment of adult patients 
with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) 
high grade serous epithelial ovarian, fallopian tube, or primary peritoneal 
cancer who are in response (complete response or partial response) to 
platinum-based chemotherapy. 
FDA 
12/2014: as monotherapy in patients with deleterious or suspected 
deleterious germline BRCA mutated (as detected by an FDA-approved 
test) advanced ovarian cancer who have been treated with three or more 
prior lines of chemotherapy. 
Costs  
Olaparib:  
300 mg orally twice daily; ex-factory price of 22,400 mg = € 5059.29,-  € 
2,845.85,- per 21 days of treatment 
Phase III results 
NEJM published online on June 4, 2017 (Robson et al.): “Olaparib for Metastatic Breast Cancer in 
Patients with a Germline BRCA Mutation” 
Background 
Olaparib is an oral poly (adenosine diphosphate–ribose) polymerase inhibitor that has promising 
antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. 
 
Methods 
We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared 
with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor 
receptor type 2 (HER2)–negative metastatic breast cancer who had received no more than two 
previous chemotherapy regimens for metastatic disease. Patients were randomly assigned, in a 2:1 
ratio, to receive olaparib tablets (300 mg twice daily) or standard therapy with single-agent 
chemotherapy of the physician’s choice (capecitabine, eribulin, or vinorelbine in 21-day cycles). The 
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primary end point was progression-free survival, which was assessed by blinded independent central 
review and was analyzed on an intention-to-treat basis. 
 
Results 
Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were 
assigned to receive standard therapy. Median progressionfree survival was significantly longer in the 
olaparib group than in the standardtherapy group (7.0 months vs. 4.2 months; hazard ratio for disease 
progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001). The response rate was 
59.9% in the olaparib group and 28.8% in the standard-therapy group. The rate of grade 3 or higher 
adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the 
rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively. 
 
Conclusion 
Among patients with HER2-negative metastatic breast cancer and a germline BRCA mutation, 
olaparib monotherapy provided a significant benefit over standard therapy; median progression-free 
survival was 2.8 months longer and the risk of disease progression or death was 42% lower with 
olaparib monotherapy than with standard therapy. (Funded by AstraZeneca; OlympiAD 
ClinicalTrials.gov number, NCT02000622.)  
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2 Leukaemia 
2.1 Idelalisib (Zydelig®) or placebo in combination with 
bendamustine and rituximab in patients with relapsed or 
refractory chronic lymphocytic leukaemia 
 
Overview 
Drug Description an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase 
Patient Indication idelalisib in combination with bendamustine and rituximab in patients with 
relapsed or refractory chronic lymphocytic leukaemia 
Incidence in 
Austria 
936 newly diagnosed per year (2014), 11.3/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase II NCT01569295 until 12/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
02/2016 (+ofatumumab) & 09/2014 (+rituximab): in combination with an anti‑
CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of 
adult patients with chronic lymphocytic leukaemia (CLL): 
 
• who have received at least one prior therapy, or 
• as first line treatment in  the presence of 17p deletion or TP53 
mutation in patients who are not eligible for any other therapies  
 
09/2014: as monotherapy for the treatment of adult patients with follicular 
lymphoma (FL) that is refractory to two prior lines of treatment  
FDA 
07/2014: 
• for relapsed chronic lymphocytic leukaemia (CLL), in combination 
with rituximab, in patients for whom rituximab alone would be 
considered appropriate therapy due to other co-morbidities 
• for relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients 
who have received at least two prior systemic therapies 
• for relapsed small lymphocytic lymphoma (SLL) in patients who have 
received at least two prior systemic therapies 
Costs 
ZYDELIG 
1 treatment cycle: twice-daily oral idelalisib (150 mg); ex-factory price of 60 
pieces 150 mg = € 3,700,-  € 3,453,- per treatment cycle 
LEVACT 
1 treatment cycle: 70 mg/m² intravenously on days 1 and 2 (assuming an 
average body surface area of 1.75 m²); ex-factory price of 500 mg =  
€ 1,505.98,-  € 735.2,- per treatment cycle 
MabThera 
Cycle 1: 375 mg/m² on day 1 (assuming an average body surface area of 
1.75 m²); ex-factory price of 500 mg = € 1,516.43,-  € 1,990.3,- per 
treatment cycle  
Cycles 2–6: 500 mg/m² on day 1 (assuming an average body surface area of 
1.75 m²); ex-factory price of 500 mg =  € 1,516.43,-  € 2,653.8,- per 
treatment cycle 
Total costs for combination therapy for the first treatment cycle: € 6,178.5,-  
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Phase III results 
Lancet 2017 March, 18(3):297-311 (Zelenetz et al.) “Idelalisib or placebo in combination with 
bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: 
interim results from a phase 3, randomised, double-blind, placebo-controlled trial” 
 
Background 
Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or 
refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant 
outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class 
targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. 
 
Methods 
For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with 
relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable 
lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous 
therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response 
system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m2 
intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m2 on day 1 of cycle 1, and 
500 mg/m2 on day 1 of cycles 2–6) in addition to either twice-daily oral idelalisib (150 mg) or placebo 
until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by 
high-risk features (IGHV, del[17p], or TP53 mutation) and refractory versus relapsed disease. The 
primary endpoint was progression-free survival assessed by an independent review committee in the 
intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number 
NCT01569295. 
 
Findings 
Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the 
idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7–18), 
median progression-free survival was 20.8 months (95% CI 16.6–26.4) in the idelalisib group and 11.1 
months (8.9–11.1) in the placebo group (hazard ratio [HR] 0.33, 95% CI 0.25–0.44; p<0.0001). The 
most frequent grade 3 or worse adverse events in the idelalisib group were neutropenia (124 [60%] of 
207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia 
(99 [47%] of 209) and thrombocytopenia (27 [13%]). An increased risk of infection was reported in the 
idelalisib group compared with the placebo group (grade ≥3 infections and infestations: 80 [39%] of 
207 vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and 
pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo 
group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) 
patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections 
in the idelalisib group and three from infections in the placebo group. 
 
Interpretation 
Idelalisib in combination with bendamustine plus rituximab improved progression-free survival 
compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic 
lymphocytic leukaemia. However, careful attention needs to be paid to management of serious 
adverse events and infections associated with this regimen during treatment selection. 
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2.2 Midostaurin (Rydapt®) plus chemotherapy for acute myeloid 
leukemia with a FLT3 mutation 
 
Overview 
Drug Description a small molecule that inhibits multiple receptor tyrosine kinases 
Patient Indication midostaurin in combination to standard chemotherapy in patients with acute 
myeloid leukemia and a FLT3 mutation 
Incidence in 
Austria 
936 newly diagnosed per year (2014), 11.3/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase II - 
Approval 
status for 
this 
indication 
EMA 
07/2004: orphan designation was granted by the European Commission to 
Novartis Europharm Limited, United Kingdom, for midostaurin for the 
treatment of acute myeloid leukaemia. 
FDA 
04/2017: for the treatment of adult patients with newly diagnosed acute 
myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as 
detected by an FDA-approved test, in combination with standard cytarabine 
and daunorubicin induction and cytarabine consolidation. 
Approval 
status for 
other 
indications 
EMA 
08/2010, orphan designation was granted by the European Commission to 
Novartis Europharm Limited, United Kingdom, for midostaurin for the 
treatment of mastocytosis. 
FDA 
04/2017: midostaurin for the treatment of adults with aggressive systemic 
mastocytosis (SM), SM with associated hematological neoplasm, or mast cell 
leukemia. 
Costs - 
Phase III results 
Lancet published online June 2017, (Stone et al.) “Midostaurin plus Chemotherapy for Acute 
Myeloid Leukemia with a FLT3 Mutation” 
 
Background 
Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted 
a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase 
inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolong 
overall survival in this population. 
 
Methods 
We screened 3277 patients, 18 to 59 years of age, who had newly diagnosed AML for FLT3 
mutations. Patients were randomly assigned to receive standard chemotherapy (induction therapy with 
daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus either 
midostaurin or placebo; those who were in remission after consolidation therapy entered a 
maintenance phase in which they received either midostaurin or placebo. Randomization was stratified 
according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD) or internal 
tandem duplication (ITD) mutation with either a high ratio (>0.7) or a low ratio (0.05 to 0.7) of mutant to 
wild-type alleles (ITD [high] and ITD [low], respectively). Allogeneic transplantation was allowed. The 
primary end point was overall survival. 
 
Results 
A total of 717 patients underwent randomization; 360 were assigned to the midostaurin group, and 
357 to the placebo group. The FLT3 subtype was ITD (high) in 214 patients, ITD (low) in 341 patients, 
and TKD in 162 patients. The treatment groups were well balanced with respect to age, race, FLT3 
subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the midostaurin 
group vs. 59.4% in the placebo group were women, P = 0.04). Overall survival was significantly longer 
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in the midostaurin group than in the placebo group (hazard ratio for death, 0.78; one-sided P = 0.009), 
as was event-free survival (hazard ratio for event or death, 0.78; one-sided P = 0.002). In both the 
primary analysis and an analysis in which data for patients who underwent transplantation were 
censored, the benefit of midostaurin was consistent across all FLT3 subtypes. The rate of severe 
adverse events was similar in the two groups. 
 
Conclusions 
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly 
prolonged overall and event-free survival among patients with AML and a FLT3 mutation. (Funded by 
the National Cancer Institute and Novartis; ClinicalTrials.gov number, NCT00651261.) 
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3 Prostate caner 
3.1 Abiraterone (Zytiga®) in combination with prednisone 
androgen-deprivation therapy in metastatic, castration-
sensitive prostate cancer 
 
Overview 
Drug Description an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17) 
Patient Indication Abiraterone in combination with prednisone androgen-deprivation therapy in 
metastatic, castration-sensitive prostate cancer 
Incidence in 
Austria 
4,499 newly diagnosed per year (2014), 124.0/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase II NCT00268476 - until 09/2017 NCT01715285 until 07/2021 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
09/2011: in combination with prednisone or prednisolone the treatment of 
metastatic castration resistant prostate cancer in adult men whose disease 
has progressed on or after a docetaxel based chemotherapy regimen. 
 
12/2012: in combination with prednisone or prednisolone for the treatment of 
metastatic castration resistant prostate cancer in adult men who are 
asymptomatic or mildly symptomatic after failure of androgen deprivation 
therapy in whom chemotherapy is not yet clinically indicated. 
FDA 04/2011: in combination with prednisone for the treatment of patients with 
metastatic castration-resistant prostate cancer. 
Costs 
Abiraterone:  
1,000 mg orally (given once daily as four 250-mg tablets); ex-factory price of 
28,000 mg = € 2,895.35,-  € 2,171.51 for 21 days of treatment  
Phase III results 
NEJM published online June 2017 (Fizazi et al.) “Abiraterone plus Prednisone in Metastatic, 
Castration-Sensitive Prostate Cancer” 
 
Background 
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated 
for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone 
acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, 
metastatic, castration-sensitive prostate cancer. 
 
Methods 
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive 
either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 
250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy 
plus dual placebos (the placebo group). The two primary end points were overall survival and 
radiographic progression-free survival. 
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Results 
After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the 
median overall survival was significantly longer in the abiraterone group than in the placebo group (not 
reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; 
P<0.001). The median length of radiographic progression-free survival was 33.0 months in the 
abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or 
death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). Significantly better outcomes in all secondary end points 
were observed in the abiraterone group, including the time until pain progression, next subsequent 
therapy for prostate cancer, initiation of chemotherapy, and prostatespecific antigen progression 
(P<0.001 for all comparisons), along with next symptomatic skeletal events (P = 0.009). These 
findings led to the unanimous recommendation by the independent data and safety monitoring 
committee that the trial be unblended and crossover be allowed for patients in the placebo group to 
receive abiraterone. Rates of grade 3 hypertension and hypokalemia were higher in the abiraterone 
group. 
 
Conclusion 
The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly 
increased overall survival and radiographic progression-free survival in men with newly diagnosed, 
metastatic, castration-sensitive prostate cancer. (Funded by Janssen Research and Development; 
LATITUDE ClinicalTrials.gov number, NCT01715285.) 
 
NEJM published online June 2017 (James et al.) “Abiraterone for Prostate Cancer Not Previously 
Treated with Hormone Therapy” 
 
Background 
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We 
assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), 
using a multigroup, multistage trial design. 
 
 
Methods 
We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate 
(1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was 
mandated for patients with node-negative, nonmetastatic disease and encouraged for those with 
positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients 
with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen 
(PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, 
whichever came first. The primary outcome measure was overall survival. The intermediate primary 
outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA 
progression or death from prostate cancer). 
 
Results 
A total of 1917 patients underwent randomization from November 2011 through January 2014. The 
median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the 
patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, 
and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median 
follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in 
the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the 
hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic 
disease. There were 248 treatment-failure events in the combination group as compared with 535 in 
the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in 
patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse 
events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% 
of the patients in the ADT-alone group (with three grade 5 events). 
 
Conclusion 
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and 
prednisolone was associated with significantly higher rates of overall and failure-free survival than 
ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, 
NCT00268476, and Current Controlled Trials number, ISRCTN78818544.) 
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4 Ovarian cancer 
4.1 Bevacizumab (Avastin®) and paclitaxel–carboplatin 
chemotherapy and secondary cytoreduction in recurrent, 
platinum-sensitive ovarian cancer 
 
Overview 
Drug Description 
a recombinant monoclonal antibody that binds to vascular endothelial 
growth factor (VEGF) and inhibits the binding to its receptors (VEGFR-1 
and VEGFR-2) 
Patient Indication 
bevacizumab in combination with carboplatin and paclitaxel or in 
combination with carboplatin and gemcitabine, followed by bevacizumab 
single agent for the treatment of recurrent epithelial ovarian, fallopian tube, 
or primary peritoneal cancer 
Incidence in 
Austria 
635 newly diagnosed per year (2014), 13.8 /100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT00565851 until 03/2019 
Approval 
status for 
this 
indication 
EMA 
04/2017: CHMP adopted an extension to an existing indication as follows: 
"Bevacizumab, in combination with carboplatin and gemcitabine or in 
combination with carboplatin and paclitaxel, is indicated for treatment of 
adult patients with first recurrence of platinum-sensitive epithelial ovarian, 
fallopian tube or primary peritoneal cancer who have not received prior 
therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–
targeted agents" 
FDA 
12/2016: in combination with carboplatin and paclitaxel or in combination 
with carboplatin and gemcitabine, followed by bevacizumab single agent 
for the treatment of recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer. 
Approval 
status for 
other 
indications 
EMA 
08/2007: in addition to platinum-based chemotherapy, is indicated for first-
line treatment of adult patients with unresectable advanced, metastatic or 
recurrent non-small-cell lung cancer other than predominantly squamous 
cell histology. 
 
12/2007: in combination with interferon alfa-2a is indicated for first-line 
treatment of adult patients with advanced and / or metastatic renal-cell 
cancer. 
 
01/2008: in combination with fluoropyrimidine-based chemotherapy is 
indicated for treatment of adult patients with metastatic carcinoma of the 
colon or rectum. 
 
06/2011: in combination with paclitaxel is indicated for first-line treatment 
of adult patients with metastatic breast cancer. For further information as 
to human-epidermal-growth-factor-receptor-2 (HER2) status. 
 
06/2011: in combination with capecitabine is indicated for first-line 
treatment of adult patients with metastatic breast cancer in whom 
treatment with other chemotherapy options including taxanes or 
anthracyclines is not considered appropriate. Patients who have received 
taxane and anthracycline-containing regimens in the adjuvant setting 
within the last 12 months should be excluded from treatment with Avastin 
in combination with capecitabine. 
 
12/2011: in combination with carboplatin and paclitaxel is indicated for the 
front-line treatment of adult patients with advanced (International 
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Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) 
epithelial ovarian, fallopian-tube, or primary peritoneal cancer. 
 
07/2014: in combination with carboplatin and gemcitabine, is indicated for 
treatment of adult patients with first recurrence of platinum-sensitive 
epithelian-ovarian, fallopian-tube or primary peritoneal cancer who have 
not received prior therapy with bevacizumab or other vascular-endothelial-
growth-factor (VEGF) inhibitors or VEGF-receptor-targeted agents. 
 
03/2015: in combination with paclitaxel and cisplatin or, alternatively, 
paclitaxel and topotecan in patients who cannot receive platinum therapy, 
is indicated for the treatment of adult patients with persistent, recurrent, or 
metastatic carcinoma of the cervix. 
 
06/2016: in combination with erlotinib, is indicated for first-line treatment of 
adult patients with unresectable advanced, metastatic or recurrent non-
squamous non-small cell lung cancer with Epidermal Growth Factor 
Receptor (EGFR) activating mutations. 
FDA 
02/2004: first-line treatment for patients with metastatic colorectal cancer - 
cancer that has spread to other parts of the body. 
 
10/2006: in combination with carboplatin and paclitaxel, for the initial 
systemic treatment of patients with unresectable, locally advanced, 
recurrent, or metastatic, non-squamous, non-small cell lung cancer. 
 
01:/2009: in combination with interferon alfa for the treatment of patients 
with metastatic renal cell carcinoma. 
 
05/2009: single agent for patients with glioblastoma, with progressive 
disease following prior therapy. 
 
01/2013: in combination with fluoropyrimidine–irinotecan- or 
fluoropyrimidine–oxaliplatin-based chemotherapy for the treatment of 
patients with metastatic colorectal cancer (mCRC) whose disease has 
progressed while on first-line treatment with a bevacizumab-containing 
regimen. 
 
08/2014: in combination with paclitaxel and either cisplatin or topotecan for 
the treatment of persistent, recurrent, or metastatic cervical cancer. 
 
11/2014: in combination with paclitaxel, pegylated liposomal doxorubicin, 
or topotecan for the treatment of patients with platinum-resistant, recurrent 
epithelial ovarian, fallopian tube, or primary peritoneal cancer. 
 
12/2016: in combination with carboplatin and paclitaxel or in combination 
with carboplatin and gemcitabine, followed by bevacizumab single agent 
for the treatment of recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer. 
Costs  
Bevacizumab: 
15 mg/kg intravenously on day 1/treatment cycle =3 weeks (assuming an 
average body weight of 70 kg); ex-factory price of 100 mg =  
€ 368,-  € 3,864,- per treatment cycle 
Phase III results 
Lancet 2017, 18:6, 779–791, (Coleman et al.): “Bevacizumab and paclitaxel–carboplatin 
chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG 
Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, 
phase 3 trial” 
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Background 
Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer 
recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of 
secondary surgical cytoreduction and bevacizumab in this population, and report the results of the 
bevacizumab component here. 
 
Methods 
The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly 
academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible 
patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, 
primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-
based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of 
platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of 
paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same 
chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as 
maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who 
participated in both the bevacizumab objective and surgical objective (which is ongoing) were 
randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without 
prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by 
treatment-free interval and participation in the surgical objective. The primary endpoint was overall 
survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number 
NCT00565851. 
 
Findings 
Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to 
standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the 
end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for 
chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had 
died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based 
on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab 
group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy 
group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free 
interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a 
sensitivity analysis of overall survival based on the audited treatment-free interval stratification data 
gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients 
who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had 
at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy 
group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared 
with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight 
[2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the 
chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in 
the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic 
syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease 
progression [n=3], sudden death [n=1], and not specified [n=1]). 
 
Interpretation 
The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until 
progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian 
cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity 
analysis based on corrected treatment-free interval stratification indicates that this strategy might be 
an important addition to the therapeutic armamentarium in these patients. 
